HC Wainwright Has Negative Estimate for VIGL FY2026 Earnings

Vigil Neuroscience, Inc. (NASDAQ:VIGL) – Equities researchers at HC Wainwright decreased their FY2026 earnings estimates for Vigil Neuroscience in a report released on Tuesday, May 27th. HC Wainwright analyst A. Fein now expects that the company will earn ($0.84) per share for the year, down from their prior forecast of ($0.64). HC Wainwright currently has a “Neutral” rating and a $8.00 target price on the stock. The consensus estimate for Vigil Neuroscience’s current full-year earnings is ($2.07) per share. HC Wainwright also issued estimates for Vigil Neuroscience’s FY2027 earnings at ($0.15) EPS, FY2028 earnings at $0.26 EPS and FY2029 earnings at $0.63 EPS.

Vigil Neuroscience (NASDAQ:VIGL) last posted its quarterly earnings results on Wednesday, May 7th. The company reported ($0.49) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.04.

A number of other research firms have also issued reports on VIGL. Stifel Nicolaus lowered Vigil Neuroscience from a “buy” rating to a “hold” rating and dropped their price target for the company from $11.00 to $8.00 in a research report on Wednesday. Citigroup cut Vigil Neuroscience to a “market perform” rating in a report on Thursday, May 22nd. William Blair downgraded Vigil Neuroscience from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 22nd. Citizens Jmp cut shares of Vigil Neuroscience from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 22nd. Finally, JMP Securities reissued a “market perform” rating on shares of Vigil Neuroscience in a report on Thursday, May 22nd. Ten investment analysts have rated the stock with a hold rating, According to MarketBeat, Vigil Neuroscience presently has an average rating of “Hold” and a consensus price target of $10.80.

Vigil Neuroscience Price Performance

VIGL opened at $7.88 on Thursday. The firm has a market capitalization of $367.78 million, a price-to-earnings ratio of -3.83 and a beta of 1.90. The company’s 50 day simple moving average is $2.79 and its two-hundred day simple moving average is $2.45. Vigil Neuroscience has a 1-year low of $1.31 and a 1-year high of $7.95.

Institutional Investors Weigh In On Vigil Neuroscience

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Cubist Systematic Strategies LLC grew its holdings in shares of Vigil Neuroscience by 53.0% during the 4th quarter. Cubist Systematic Strategies LLC now owns 24,120 shares of the company’s stock worth $41,000 after purchasing an additional 8,358 shares during the period. Jane Street Group LLC acquired a new position in Vigil Neuroscience in the fourth quarter valued at about $83,000. Barclays PLC lifted its position in Vigil Neuroscience by 43.6% in the fourth quarter. Barclays PLC now owns 64,049 shares of the company’s stock valued at $109,000 after buying an additional 19,436 shares during the last quarter. Northern Trust Corp boosted its stake in Vigil Neuroscience by 29.0% during the fourth quarter. Northern Trust Corp now owns 64,737 shares of the company’s stock worth $110,000 after buying an additional 14,572 shares during the period. Finally, Two Sigma Advisers LP increased its position in shares of Vigil Neuroscience by 243.8% during the fourth quarter. Two Sigma Advisers LP now owns 69,100 shares of the company’s stock valued at $117,000 after acquiring an additional 49,000 shares during the last quarter. Hedge funds and other institutional investors own 83.64% of the company’s stock.

About Vigil Neuroscience

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.